Results 41 to 50 of about 4,420 (152)

Gene knockdown of angiopoietin-like protein 3 reduces the occurrence and development of thoracic aortic aneurysms [PDF]

Jichu yixue yu linchuang, 2021
Objective To explore the role of angiopoietin-like protein 3 (ANGPTL3) in the development of thoracic aortic aneurysm (TAA) and its possible mechanism. Methods The TAA patients who underwent open surgical repair in Beijing Anzhen Hospital were selected
YU Hua-hui, JIAO Xiao-lu, YANG Yun-yun, LI Fan, SUN Qiu-ju, YU Yu, LYU Qian-wen, QIN Yan-wen
doaj  

Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation

Bioscience Reports, 2014
Homozygosity of loss-of-function mutations in ANGPTL3 (angiopoietin-like protein 3)-gene results in FHBL2 (familial combined hypolipidaemia, OMIM #605019) characterized by the reduction of all major plasma lipoprotein classes, which includes VLDL (very ...
Anna Tikka, Jarkko Soronen, Pirkka‑Pekka Laurila, Jari Metso, Christian Ehnholm, Matti Jauhiainen   +5 more
doaj   +1 more source

ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins [PDF]

, 2020
Loss-of-function (LOF) mutations in ANGPTL3, an inhibitor of lipoprotein lipase (LPL), cause a drastic reduction of serum lipoproteins and protect against the development of atherosclerotic cardiovascular disease.
Ruhanen H, Arca M, Olkkonen VM, D'Erasmo L, Dalli J, Käkelä R, Di Costanzo A, Zhou Y, Partanen J, Minicocci I, Metso J, Taskinen JH, Haridas PAN, Palmas F, Jauhiainen M   +14 more
core   +2 more sources

High-Serum Angiopoietin-Like Protein 3 Levels Associated with Cardiovascular Outcome in Patients with Coronary Artery Disease

International Journal of Hypertension, 2020
Background. Angiopoietin-like protein 3 (ANGPTL3) plays a pivotal role in lipid metabolism and angiogenesis, and there is growing interest regarding the association between ANGPTL3 and coronary artery disease (CAD). This study aims to investigate whether
Ming-Chun Chen, Bang-Gee Hsu, Chung-Jen Lee, Ji-Hung Wang   +3 more
doaj   +1 more source

ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance[S]

Journal of Lipid Research, 2017
Angiopoietin-like (ANGPTL)3 and ANGPTL8 are secreted proteins and inhibitors of LPL-mediated plasma triglyceride (TG) clearance. It is unclear how these two ANGPTL proteins interact to regulate LPL activity.
Jorge F. Haller, Ivory J. Mintah, Lisa M. Shihanian, Panayiotis Stevis, David Buckler, Corey A. Alexa-Braun, Sandra Kleiner, Serena Banfi, Jonathan C. Cohen, Helen H. Hobbs, George D. Yancopoulos, Andrew J. Murphy, Viktoria Gusarova, Jesper Gromada   +13 more
doaj   +1 more source

OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD

Advanced Science, EarlyView.
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li, Jingyue Song, Kaili Ma, Shunan Tang, Shuqian Wang, Wenya Ji, Chen Lu, Ting Zhang, Huaping Zheng, Xiaowei Zheng, Shanshan Lai, Cheng Deng   +11 more
wiley   +1 more source

Correlation Between the Levels of ANGPTL3, ANGPTL4, ANGPTL8 and Postprandial Triglyceride-Rich Lipoprotein (TRL)

, 2023
Tingxue Zhang,1,2 Yilin Hou,1,2 Min Liu,2 Xiaoyu Hou,1,2 Yong Tang,2 Luping Ren,2 Guangyao Song1,2 1Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China; 2Department of Endocrinology, Hebei General ...
Zhang T, Ren L, Liu M, Hou X, Hou Y, Song G, Tang Y   +6 more
core  

Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance

Journal of Lipid Research, 2020
Angiopoietin-like protein (ANGPTL)3 regulates plasma lipids by inhibiting LPL and endothelial lipase (EL). ANGPTL3 inactivation lowers LDL-C independently of the classical LDLR-mediated pathway and represents a promising therapeutic approach for ...
Rene C. Adam, Ivory J. Mintah, Corey A. Alexa-Braun, Lisa M. Shihanian, Joseph S. Lee, Poulabi Banerjee, Sara C. Hamon, Hye In Kim, Jonathan C. Cohen, Helen H. Hobbs, Cristopher Van Hout, Jesper Gromada, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman, Viktoria Gusarova   +15 more
doaj   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub, Armin Sepp, Amin Rostami‐Hodjegan, Brahim Achour   +3 more
wiley   +1 more source

In silico prediction of ANGPTL3-EL interaction

, 2022
Angiopoietin-like protein 3 (ANGPTL3) plays an essential role in lipoprotein metabolism. ANGPTL3 inhibits lipoprotein lipase (LPL), that hydrolyzes triglycerides on VLDL, and endothelial lipase (EL) that hydrolyzes phospholipids on HDL.
L. Palazzolo, L. Montavoci, O. Ben Mariem, U. Guerrini, L. Calabresi, S. Saporiti, T. Laurenzi, I. Eberini   +7 more
core